Diyabette metformin kullanımının B12 vitamin düzeyleri ile ilişkisi
[ X ]
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Çanakkale Onsekiz Mart Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu çalışmanın amacı Diabetes Mellituslu hastalarda; metformin kullanan ve kullanmayan hastaları karşılaştırarak metforminin vitamin B12 düzeyine etkisini araştırmaktır. Yöntem: Kesitsel analitik desendeki çalışma 01.12.2019-01.04.2020 tarihleri arasında yapıldı. Araştırma evreni ÇOMÜ Sağlık Uygulama ve Araştırma Hastanesi'ne başvurmuş DM'u olan 18 yaş üstü yetişkinlerdir. Son 1 yılda, HbA1c ve vitamin B12 düzeylerine bakılmış 242 hasta, çalışmanın örneklemini oluşturdu. 1.grup metformin kullanan 121 DM'si olan hasta, 2.grup ise metformin kullanmayan 121 DM'si olan hastalar olarak belirlendi. Bulgular: Metformin kullanan 121 hastanın ortalama vitamin B12 değerleri 278,8±85,4 iken metformin kullanmayan 121 hastanın ortalama vitamin B12 değerleri 424,5±238,6 olarak hesaplanmıştır. Vitamin B12 düzeyleri düşük olanların oranı metformin kullananlarda (X2=72,585; p<0,001) kullanmayanlara göre anlamlı bulunmuştur. Metformin kullananlarda vitamin B12 düzeylerinde düşüklük görülme riski metformin kullanmayanlara göre 7,5 (%95 GA: 3,6-11,326) kat daha yüksektir. PPİ ilaç kullananlarda (X2=34,899; p<0,001) kullanmayanlara göre anlamlı bulunmuştur. PPI kullananlarda vitamin B12 düzeyinde düşüklük görülme riski kullanmayanlara göre 1,9 kat (%95 GA: 0,8-3,054) daha yüksektir. Diğer antidiyabetik ilaç kullananlarda (X2=27,432; p<0,001), HT ilaç kullananlarda (X2=15,678; p<0,001) ve HL ilacı kullananlarda (X2=11,369; p=0,003) bu ilaçları kullanmayanlara göre anlamlı yüksekti. Vitamin B12 düzeyleri ile sırasıyla, diğer KVH ilaç kullanımı ve endokrinolojik ilaç kullanımı ile arasında istatiksel olarak anlamlı fark saptanmadı. Sonuçlar: Metformin kullanımının vitamin B12 düzeylerinde anlamlı bir düşüşe sebep olduğu görülmüştür. PPİ kullanımının vitamin B12 düzeylerinde anlamlı bir düşüşe sebep olduğu görülmüştür.
Objective: The aim of this study in patients with Diabetes Mellitus; To investigate the effect of metformin on vitamin B12 level by comparing the patients using and not using metformin. Method: The study in the cross-sectional analytical design was conducted between 01.12.2019-01.04.2020. The population of the research is the adults over the age of 18 who have applied to the ÇOMÜ Health Practice and Research Hospital. In the last year, 242 patients whose HbA1c and vitamin B12 levels were measured constituted the sample of the study. The first group was determined as 121 patients with DM using metformin, and the second group as 121 patients who did not use metformin. Results: While the mean vitamin B12 values of 121 patients using metformin were 278.8 ± 85.4, the mean vitamin B12 values of 121 patients not using metformin were calculated as 424.5 ± 238.6. The proportion of those with low vitamin B12 levels was found to be significant in those using metformin (X2 = 72.585; p <0.001) compared to those who did not. The risk of low vitamin B12 levels in metformin users is 7.5 (95% CI: 3.6-11.326) times higher than those who do not use metformin. PPI was found to be significant in patients who used medication (X2 = 34.899; p <0.001) compared to those who did not. The risk of low vitamin B12 level in PPI users is 1.9 times higher (95% CI: 0.8-3.054) than in non-users. It was significantly higher in those using other antidiabetic drugs (X2 = 27.432; p <0.001), those using HT drugs (X2 = 15.678; p <0.001) and those using HL drugs (X2 = 11.369; p = 0.003) compared to those who did not use these drugs. No statistically significant difference was found between vitamin B12 levels and other CVD drug use and endocrinological drug use, respectively. Conclusions: It was observed that the use of metformin caused a decrease in vitamin B12 levels. It has been observed that the use of PPIs causes a decrease in vitamin B12 levels.
Objective: The aim of this study in patients with Diabetes Mellitus; To investigate the effect of metformin on vitamin B12 level by comparing the patients using and not using metformin. Method: The study in the cross-sectional analytical design was conducted between 01.12.2019-01.04.2020. The population of the research is the adults over the age of 18 who have applied to the ÇOMÜ Health Practice and Research Hospital. In the last year, 242 patients whose HbA1c and vitamin B12 levels were measured constituted the sample of the study. The first group was determined as 121 patients with DM using metformin, and the second group as 121 patients who did not use metformin. Results: While the mean vitamin B12 values of 121 patients using metformin were 278.8 ± 85.4, the mean vitamin B12 values of 121 patients not using metformin were calculated as 424.5 ± 238.6. The proportion of those with low vitamin B12 levels was found to be significant in those using metformin (X2 = 72.585; p <0.001) compared to those who did not. The risk of low vitamin B12 levels in metformin users is 7.5 (95% CI: 3.6-11.326) times higher than those who do not use metformin. PPI was found to be significant in patients who used medication (X2 = 34.899; p <0.001) compared to those who did not. The risk of low vitamin B12 level in PPI users is 1.9 times higher (95% CI: 0.8-3.054) than in non-users. It was significantly higher in those using other antidiabetic drugs (X2 = 27.432; p <0.001), those using HT drugs (X2 = 15.678; p <0.001) and those using HL drugs (X2 = 11.369; p = 0.003) compared to those who did not use these drugs. No statistically significant difference was found between vitamin B12 levels and other CVD drug use and endocrinological drug use, respectively. Conclusions: It was observed that the use of metformin caused a decrease in vitamin B12 levels. It has been observed that the use of PPIs causes a decrease in vitamin B12 levels.
Açıklama
Tıp Fakültesi, Aile Hekimliği Ana Bilim Dalı
Anahtar Kelimeler
Aile Hekimliği, Family Medicine
